SHORT MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 15:41:27 26/06/2024 BST | ||
| 8.29 EUR | +0.48% |
|
| Current month | +2.61% | ||
| 1 month | -4.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 8.29 | +0.48% |
| 25/06/24 | 8.25 | +3.38% |
| 24/06/24 | 7.98 | -3.39% |
| 21/06/24 | 8.26 | +2.10% |
| 20/06/24 | 8.09 | -1.70% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 03:41 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU80MA |
| ISIN | DE000VU80MA6 |
| Date issued | 23/06/2023 |
| Strike | 311.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.35 € |
|---|---|
| Lowest since issue | 1.77 € |
| Spread | 0.03 € |
| Spread % | 0.36% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
223.2
USD
Average target price
283.2
USD
Spread / Average Target
+26.87%
- Stock Market
- Certificates
- Certificat
